ng Emisphere's drug delivery technology, or Emisphere's ability
to fund such efforts with or without partners. Emisphere undertakes no
obligation to update any of these statements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only
as to the date hereof. Accordingly any forward-looking statements should be
read in conjunction with the additional risks and uncertainties detailed in
Emisphere's filings with the Securities and Exchange Commission, including
those factors discussed under the caption "Risk Factors" in Emisphere's
Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, filed
on May 7, 2008.
CONDENSED STATEMENTS OF OPERATIONS
For the three months ended March 31, 2008 and 2007
(in thousands, except share and per share data)
(unaudited)
For the three months ended
March 31,
2008 2007
Revenue $154 $2,809
Costs and expenses:
Research and development 3,832 5,451
General and administrative expenses 2,693 4,145
Gain on disposal of fixed assets (135) -
Depreciation and amortization 226 315
Total costs and expenses 6,616 9,911
Operating income (loss) (6,462) (7,102)
Other income (expense):
Other income 99 314
Sale of patents 1,500 -
Change in fair value of
derivative instruments
'/>"/>
SOURCE Emisphere Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Emisphere Technologies, Inc. Announces Conference Call for First Quarter 2008 Financial Results2.
Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements3.
Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 20084.
Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results5.
Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results6.
Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 127.
Emisphere Technologies to Present at BIO CEO & Investor Conference on February 128.
Emisphere to Host Business Strategy Conference Call on February 79.
Emisphere Technologies, Inc. Moves Into New Corporate Headquarters10.
Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology11.
Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation